Dr Sherry Gu joined WuXi Biologics in 2017, and has built a strong CMC team in US & EU, establishing the global footprint and business growth by leveraging the company’s strong technical capability, robust global capacity, and service flexibility.
Dr. Sherry GU got her Ph.D. in Biochemical Engineering from Massachusetts Institute of Technology. Prior to joining WuXi Biologics, she had worked in the biopharmaceutical field for more than twenty years, including two years at Bristol Myers Squibb and eighteen years at Eli Lilly and Company. During her time at Lilly, she made significant technical contributions including establishing the mammalian cell culture platform, which enabled multiple Lilly biological product approvals. She also had several significant leadership roles, including Director of Cell Line & Upstream Development, Director of Downstream Development, Program Team Leader, and Autoimmune Portfolio Leader, which helped her gain a deep understanding of drug development throughout product lifecycle.